Positive News SentimentPositive NewsNASDAQ:FGEN FibroGen (FGEN) Stock Price, News & Analysis $0.71 -0.01 (-1.05%) (As of 09:40 AM ET) Add Compare Share Share Today's Range$0.71▼$0.7350-Day Range$0.69▼$1.3752-Week Range$0.33▼$2.93Volume65,776 shsAverage Volume2.61 million shsMarket Capitalization$71.02 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get FibroGen alerts: Email Address FibroGen MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside177.2% Upside$2.00 Price TargetShort InterestBearish8.13% of Shares Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$25,884 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.05) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.01 out of 5 starsMedical Sector179th out of 879 stocksPharmaceutical Preparations Industry69th out of 417 stocks 2.8 Analyst's Opinion Consensus RatingFibroGen has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageFibroGen has only been the subject of 1 research reports in the past 90 days.Read more about FibroGen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.13% of the outstanding shares of FibroGen have been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroGen has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFibroGen does not currently pay a dividend.Dividend GrowthFibroGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFibroGen has received a 74.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for the autoimmune system", "Clinical research services for cancer", and "Clinical research services for deficiency diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for FibroGen is -0.84. Previous Next 3.3 News and Social Media Coverage News SentimentFibroGen has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for FibroGen this week, compared to 2 articles on an average week.Search Interest3 people have searched for FGEN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, FibroGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,884.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.98% of the stock of FibroGen is held by insiders.Percentage Held by Institutions72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about FibroGen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for FibroGen are expected to grow in the coming year, from ($1.05) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroGen is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroGen is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about FibroGen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover About FibroGen Stock (NASDAQ:FGEN)FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Read More FGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FGEN Stock News HeadlinesJune 14, 2024 | insidertrades.comFibroGen, Inc. (NASDAQ:FGEN) Insider Deyaa Adib Buys 22,123 SharesJune 3, 2024 | globenewswire.comFibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical TrialsJuly 8, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.June 3, 2024 | globenewswire.comFibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid TumorsMay 28, 2024 | seekingalpha.comPamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial StrainsMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 23, 2024 | globenewswire.comFibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual MeetingMay 8, 2024 | finance.yahoo.comFibroGen First Quarter 2024 Earnings: Beats ExpectationsJuly 8, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.May 7, 2024 | msn.comFibroGen Shares Climb On Strong Q1 SalesMay 7, 2024 | finance.yahoo.comFibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call TranscriptMay 7, 2024 | markets.businessinsider.comGoldman Sachs Remains a Sell on FibroGen (FGEN)May 7, 2024 | finance.yahoo.comFibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 7, 2024 | globenewswire.comFibroGen to Participate in Upcoming Investor ConferencesMay 6, 2024 | msn.comFGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | finance.yahoo.comFibroGen Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comFibroGen Reports First Quarter 2024 Financial ResultsMay 5, 2024 | markets.businessinsider.comHere's what Wall Street expects from FibroGen's earningsSee More Headlines Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/08/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FGEN CUSIPN/A CIK921299 Webwww.fibrogen.com Phone(415) 978-1200Fax415-978-1902Employees486Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+177.2%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-284,230,000.00 Net Margins-143.57% Pretax Margin-145.04% Return on EquityN/A Return on Assets-46.06% Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick Ratio1.27 Sales & Book Value Annual Sales$147.75 million Price / Sales0.49 Cash FlowN/A Price / Cash FlowN/A Book Value($1.87) per share Price / Book-0.39Miscellaneous Outstanding Shares99,470,000Free Float97,504,000Market Cap$71.78 million OptionableOptionable Beta0.71 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Thane Wettig (Age 59)CEO & Director Comp: $941.79kMr. Juan Graham (Age 47)Senior VP & CFO Comp: $892.49kMs. Christine L. Chung (Age 56)Senior Vice President of China Operations Comp: $915.36kDr. Barry A. Berkowitz Ph.D.FounderDr. John J. Hunter Ph.D. (Age 61)Chief Scientific Officer David DeLuciaVice President of Corporate FP&A and Investor RelationsMr. Michael D. Lowenstein J.D.Ph.D., Chief Legal OfficerMs. Tricia StewartChief People OfficerMr. Kirk A. Christoffersen MBA (Age 55)Chief Business Officer Dr. Rahul Rajan Kaushik Ph.D.Senior Vice President of Pharmaceutical Development, Technical Operations & ManufacturingMore ExecutivesKey CompetitorsSeres TherapeuticsNASDAQ:MCRBALX OncologyNASDAQ:ALXOEnanta PharmaceuticalsNASDAQ:ENTARevance TherapeuticsNASDAQ:RVNCNature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInsiders & InstitutionsDeyaa AdibBought 22,123 shares on 6/12/2024Total: $25,883.91 ($1.17/share)Jacobs Levy Equity Management Inc.Sold 281,898 shares on 5/16/2024Ownership: 2.219%Public Employees Retirement System of OhioSold 56,407 shares on 5/15/2024Ownership: 0.121%Alpine Global Management LLCBought 10,752 shares on 5/15/2024Ownership: 0.011%Delap Wealth Advisory LLCBought 11,406 shares on 5/14/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions FGEN Stock Analysis - Frequently Asked Questions How have FGEN shares performed this year? FibroGen's stock was trading at $0.8863 at the start of the year. Since then, FGEN stock has decreased by 18.6% and is now trading at $0.7216. View the best growth stocks for 2024 here. How were FibroGen's earnings last quarter? FibroGen, Inc. (NASDAQ:FGEN) released its quarterly earnings results on Monday, May, 6th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.02. The biopharmaceutical company had revenue of $55.90 million for the quarter, compared to analyst estimates of $41 million. When did FibroGen IPO? FibroGen (FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. How do I buy shares of FibroGen? Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that FibroGen investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW) and NIC (EGOV). This page (NASDAQ:FGEN) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
